Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

NCT06774131 is registered in ClinicalTrials.gov with UroGen Pharma Ltd. as lead sponsor.

NCT NCT06774131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
Lead sponsor
UroGen Pharma Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
August 6, 2025
Completion date
March 31, 2028
Enrollment
70 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

upper urinary tract urothelial carcinoma, urothelial carcinoma